NTRB
Price
$5.34
Change
+$0.11 (+2.10%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
58.09M
8 days until earnings call
STOK
Price
$9.87
Change
+$0.35 (+3.68%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
498.6M
18 days until earnings call
Ad is loading...

NTRB vs STOK

Header iconNTRB vs STOK Comparison
Open Charts NTRB vs STOKBanner chart's image
Nutriband
Price$5.34
Change+$0.11 (+2.10%)
Volume$252
Capitalization58.09M
Stoke Therapeutics
Price$9.87
Change+$0.35 (+3.68%)
Volume$31.04K
Capitalization498.6M
NTRB vs STOK Comparison Chart
Loading...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTRB vs. STOK commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a StrongBuy and STOK is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (NTRB: $5.23 vs. STOK: $9.52)
Brand notoriety: NTRB and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 50% vs. STOK: 125%
Market capitalization -- NTRB: $58.09M vs. STOK: $498.6M
NTRB [@Biotechnology] is valued at $58.09M. STOK’s [@Biotechnology] market capitalization is $498.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 0 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 0 green, 5 red.
According to our system of comparison, STOK is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 6 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • NTRB’s TA Score: 6 bullish, 3 bearish.
  • STOK’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NTRB is a better buy in the short-term than STOK.

Price Growth

NTRB (@Biotechnology) experienced а +3.98% price change this week, while STOK (@Biotechnology) price change was +25.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

NTRB is expected to report earnings on Jul 02, 2025.

STOK is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($499M) has a higher market cap than NTRB($58.1M). NTRB YTD gains are higher at: 11.040 vs. STOK (-13.690). NTRB has higher annual earnings (EBITDA): -6.52M vs. STOK (-115.03M). STOK has more cash in the bank: 239M vs. NTRB (5.7M). NTRB has less debt than STOK: NTRB (200K) vs STOK (2.3M). STOK has higher revenues than NTRB: STOK (16.7M) vs NTRB (2.02M).
NTRBSTOKNTRB / STOK
Capitalization58.1M499M12%
EBITDA-6.52M-115.03M6%
Gain YTD11.040-13.690-81%
P/E RatioN/AN/A-
Revenue2.02M16.7M12%
Total Cash5.7M239M2%
Total Debt200K2.3M9%
FUNDAMENTALS RATINGS
NTRB vs STOK: Fundamental Ratings
NTRB
STOK
OUTLOOK RATING
1..100
226
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
6355
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (39) in the null industry is in the same range as NTRB (57). This means that STOK’s stock grew similarly to NTRB’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as NTRB (100). This means that STOK’s stock grew similarly to NTRB’s over the last 12 months.

STOK's SMR Rating (94) in the null industry is in the same range as NTRB (95). This means that STOK’s stock grew similarly to NTRB’s over the last 12 months.

STOK's Price Growth Rating (55) in the null industry is in the same range as NTRB (63). This means that STOK’s stock grew similarly to NTRB’s over the last 12 months.

STOK's P/E Growth Rating (100) in the null industry is in the same range as NTRB (100). This means that STOK’s stock grew similarly to NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRBSTOK
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 21 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UMPIX49.75N/A
N/A
ProFunds UltraMid Cap Inv
MTCBX35.60N/A
N/A
MFS Technology B
DRDCX24.46N/A
N/A
Dearborn Partners Rising Dividend C
HOOFX26.84N/A
N/A
Hartford Schroders US Small Cap Opps F
CMIUX14.01N/A
N/A
Six Circles Mgd Eq Port Intl Uncons

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and VRAX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and VRAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
+3.36%
VRAX - NTRB
31%
Poorly correlated
+6.34%
NOXOF - NTRB
29%
Poorly correlated
N/A
SYRE - NTRB
27%
Poorly correlated
+1.86%
STOK - NTRB
27%
Poorly correlated
+3.25%
MBRX - NTRB
24%
Poorly correlated
-2.38%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+3.25%
IDYA - STOK
50%
Loosely correlated
+0.91%
QTTB - STOK
49%
Loosely correlated
-1.05%
RNA - STOK
49%
Loosely correlated
+4.18%
RCKT - STOK
48%
Loosely correlated
+2.44%
DNLI - STOK
45%
Loosely correlated
+1.85%
More